Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Urinary NGAL-Positive Acute Kidney Injury and Poor Long-term Outcomes in Hospitalized Patients.

Singer E, Schrezenmeier EV, Elger A, Seelow ER, Krannich A, Luft FC, Schmidt-Ott KM.

Kidney Int Rep. 2016 Jul 25;1(3):114-124. doi: 10.1016/j.ekir.2016.07.003. eCollection 2016 Sep.

2.

Combined renin-angiotensin-aldosterone system blockade and statin therapy effectively reduces the risk of cerebrovascular accident in autosomal dominant polycystic kidney disease: a nationwide population-based cohort study.

Sung PH, Chiang HJ, Lee MS, Chiang JY, Yip HK, Yang YH.

Oncotarget. 2017 Jun 27;8(37):61570-61582. doi: 10.18632/oncotarget.18636. eCollection 2017 Sep 22.

3.

Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial.

Lee MS, Lee FY, Chen YL, Sung PH, Chiang HJ, Chen KH, Huang TH, Chen YL, Chiang JY, Yin TC, Chang HW, Yip HK.

Oncotarget. 2017 Mar 14;8(11):17750-17762. doi: 10.18632/oncotarget.14831.

4.

Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.

Florens N, Calzada C, Lyasko E, Juillard L, Soulage CO.

Toxins (Basel). 2016 Dec 16;8(12). pii: E376. doi: 10.3390/toxins8120376. Review.

5.

Statins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis Risk.

Liu JC, Hsu YP, Wu SY.

PLoS One. 2016 Sep 15;11(9):e0162588. doi: 10.1371/journal.pone.0162588. eCollection 2016.

6.

Eligibility for Statin Treatment in Korean Subjects with Reduced Renal Function: An Observational Study.

Moon BS, Kim J, Kim JH, Hyun YY, Park SE, Oh HG, Park CY, Lee WY, Oh KW, Lee KB, Kim H, Park SW, Rhee EJ.

Endocrinol Metab (Seoul). 2016 Sep;31(3):402-409. doi: 10.3803/EnM.2016.31.3.402. Epub 2016 Aug 26.

7.

Peripheral blood-derived endothelial progenitor cell therapy prevented deterioration of chronic kidney disease in rats.

Huang TH, Chen YT, Sung PH, Chiang HJ, Chen YL, Chai HT, Chung SY, Tsai TH, Yang CC, Chen CH, Chen YL, Chang HW, Sun CK, Yip HK.

Am J Transl Res. 2015 May 15;7(5):804-24. eCollection 2015.

8.

Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation.

Aftab W, Gazallo J, Motabar A, Varadrajan P, Deedwania PC, Pai RG.

Int J Angiol. 2015 Jun;24(2):105-12. doi: 10.1055/s-0035-1547373.

9.

Runx2 Expression in Smooth Muscle Cells Is Required for Arterial Medial Calcification in Mice.

Lin ME, Chen T, Leaf EM, Speer MY, Giachelli CM.

Am J Pathol. 2015 Jul;185(7):1958-69. doi: 10.1016/j.ajpath.2015.03.020. Epub 2015 May 15.

10.

Consensus statement on management of dyslipidemia in Indian subjects.

Chandra KS, Bansal M, Nair T, Iyengar SS, Gupta R, Manchanda SC, Mohanan PP, Rao VD, Manjunath CN, Sawhney JP, Sinha N, Pancholia AK, Mishra S, Kasliwal RR, Kumar S, Krishnan U, Kalra S, Misra A, Shrivastava U, Gulati S.

Indian Heart J. 2014 Dec;66 Suppl 3:S1-51. doi: 10.1016/j.ihj.2014.12.001. Epub 2014 Dec 24. Review. No abstract available.

11.

A novel therapeutic effect of statins on nephrogenic diabetes insipidus.

Bonfrate L, Procino G, Wang DQ, Svelto M, Portincasa P.

J Cell Mol Med. 2015 Feb;19(2):265-82. doi: 10.1111/jcmm.12422. Epub 2015 Jan 16. Review.

12.

Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.

Zhang X, Xiang C, Zhou YH, Jiang A, Qin YY, He J.

BMC Cardiovasc Disord. 2014 Feb 17;14:19. doi: 10.1186/1471-2261-14-19. Review.

13.

Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease.

Franczyk-Skóra B, Gluba A, Banach M, Rysz J.

Arch Med Sci. 2013 Dec 30;9(6):1019-27. doi: 10.5114/aoms.2013.39792. Epub 2013 Dec 26.

14.

Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.

Scarpioni R, Ricardi M, Albertazzi V, Melfa L.

World J Nephrol. 2012 Dec 6;1(6):184-94. doi: 10.5527/wjn.v1.i6.184. Review.

15.

Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.

Rahman M, Baimbridge C, Davis BR, Barzilay JI, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S, Stanford C; ALLHAT Collaborative Research Group.

Clin Nephrol. 2013 Oct;80(4):235-48. doi: 10.5414/CN107922.

17.

Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.

Erickson KF, Japa S, Owens DK, Chertow GM, Garber AM, Goldhaber-Fiebert JD.

J Am Coll Cardiol. 2013 Mar 26;61(12):1250-8.

18.

Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.

Iyngkaran P, Thomas M, Majoni W, Anavekar NS, Ronco C.

Cardiorenal Med. 2012 Dec;2(4):281-297. Epub 2012 Oct 31.

19.

Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review.

Naderi S, Foody JM.

Int J Nephrol Renovasc Dis. 2012;5:165-9. doi: 10.2147/IJNRD.S28159. Epub 2012 Dec 20.

20.

Pharmacologic management of chronic reno-cardiac syndrome.

Hawwa N, Schreiber MJ Jr, Tang WH.

Curr Heart Fail Rep. 2013 Mar;10(1):54-62. doi: 10.1007/s11897-012-0122-8. Review.

Supplemental Content

Support Center